HB-101 is under clinical development by Hookipa Pharma and currently in Phase II for Cytomegalovirus (HHV-5) Infections. According to GlobalData, Phase II drugs for Cytomegalovirus (HHV-5) Infections have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HB-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

HB-101 overview

HB-101 (Vaxwave) is under development for the prevention of cytomegalovirus infections in solid organ transplant patients. It is administered intramuscularly. It is a bivalent vaccine containing two recombinant, replication-deficient lymphocytic choriomeningitis virus (rLCMV) vectors, one expressing the pp65 protein and one expressing the gB protein of human cytomegalovirus (HCMV). It is based on Vaxwave technology.

See Also:

Hookipa Pharma overview

Hookipa Pharma (Hookipa) is a clinical-stage biopharmaceutical company that develops novel class of immunotherapeutics against infectious diseases and cancers. Its pipeline products include HB-101, a prophylactic cytomegalovirus vaccine candidate; HB-202 and HB-201, immuno-oncology product candidates for the treatment of human papillomavirus-positive cancers; and HB-301, targeting prostate cancer. Hookipa’s proprietary arenavirus-based technologies, VaxWave, a replication-deficient viral vector, and TheraT, a replication-attenuated viral vector, are designed to induce antigen specific cytotoxic T cells and pathogen-neutralizing antibodies for prophylactic and therapeutic purposes activating body’s immune response. The company collaborates with Gilead Sciences Inc for the development of immunotherapies to treat HIV and Hepatitis B. It operates a research and preclinical development center in Vienna, Austria. Hookipa is headquartered in New York City, New York, the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

For a complete picture of HB-101’s drug-specific PTSR and LoA scores, buy the report here.